Oppenheimer Asset Management Inc. trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 15.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,898 shares of the medical research company’s stock after selling 549 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Bio-Rad Laboratories were worth $673,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of BIO. Security National Trust Co. bought a new position in Bio-Rad Laboratories during the 3rd quarter worth $125,000. First Republic Investment Management Inc. bought a new position in Bio-Rad Laboratories during the 3rd quarter worth $208,000. Regentatlantic Capital LLC bought a new position in Bio-Rad Laboratories during the 3rd quarter worth $222,000. We Are One Seven LLC bought a new position in Bio-Rad Laboratories during the 3rd quarter worth $254,000. Finally, Atria Investments LLC bought a new position in Bio-Rad Laboratories during the 3rd quarter worth $337,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Shares of BIO stock opened at $248.85 on Monday. The company has a quick ratio of 3.16, a current ratio of 4.49 and a debt-to-equity ratio of 0.09. Bio-Rad Laboratories, Inc. has a 1 year low of $220.05 and a 1 year high of $345.15. The firm has a market cap of $7.46 billion, a price-to-earnings ratio of 60.70, a price-to-earnings-growth ratio of 2.45 and a beta of 1.21.
A number of brokerages recently commented on BIO. Zacks Investment Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 3rd. Barclays reduced their price target on Bio-Rad Laboratories from $345.00 to $315.00 and set an “equal weight” rating for the company in a research report on Friday, November 2nd. Finally, Goldman Sachs Group assumed coverage on Bio-Rad Laboratories in a research report on Wednesday, October 17th. They set a “buy” rating and a $350.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $338.43.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Read More: Penny Stocks
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.